Consumer medicine information

Fluorouracil Viatris

Fluorouracil

BRAND INFORMATION

Brand name

Fluorouracil Viatris

Active ingredient

Fluorouracil

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Fluorouracil Viatris.

SUMMARY CMI

FLUOROURACIL VIATRIS

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I using FLUOROURACIL VIATRIS?

FLUOROURACIL VIATRIS contains the active ingredient fluorouracil. FLUOROURACIL VIATRIS is used to treat solar keratoses, also known as actinic keratoses or sunspots and Bowen's disease (type of skin cancer)

For more information, see Section 1. Why am I using FLUOROURACIL VIATRIS? in the full CMI.

2. What should I know before I use FLUOROURACIL VIATRIS?

Do not use if you have ever had an allergic reaction to fluorouracil or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I use FLUOROURACIL VIATRIS? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with FLUOROURACIL VIATRIS and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use FLUOROURACIL VIATRIS?

Carefully follow all directions given by your doctor or other healthcare professionals.

  • Apply FLUOROURACIL VIATRIS once or twice daily as advised by your doctor.

More instructions can be found in Section 4. How do I use FLUOROURACIL VIATRIS? in the full CMI.

5. What should I know while using FLUOROURACIL VIATRIS?

Things you should do
  • Remind any doctor, dentist or pharmacist you visit that you are using FLUOROURACIL VIATRIS.
  • Limit your exposure to sun during and immediately following treatment with FLUOROURACIL VIATRIS.
  • Apply a broad-spectrum sunscreen every day before going outdoors, and regularly reapply during the day, except directly on the treatment area.
  • If you become pregnant while using FLUOROURACIL VIATRIS stop using it and tell your doctor immediately.
Things you should not do
  • Do not let FLUOROURACIL VIATRIS come into contact with the eyes, eyelids, nostrils or mouth. FLUOROURACIL VIATRIS is highly irritating to skin and the eyes.
Looking after your medicine
  • Keep FLUOROURACIL VIATRIS in a cool dry place where the temperature stays below 25°C and protect from heat.
  • Keep out of reach of children.

For more information, see Section 5. What should I know while using FLUOROURACIL VIATRIS? in the full CMI.

6. Are there any side effects?

Common side effects include soreness and pain, itchiness or irritation, darkening or reddening of the skin, burning, crusting, increased sensitivity of the skin to the sun, rash, dermatitis, and scarring.

Serious side effects include stomach problems such as severe pain, cramps, bloody diarrhoea and vomiting, swelling and soreness of the mouth and tongue, fever and chills, or severe pain or ulceration at the site of application.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.



FULL CMI

FLUOROURACIL VIATRIS

Active ingredient(s): Fluorouracil


Consumer Medicine Information (CMI)

This leaflet provides important information about using FLUOROURACIL VIATRIS. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using FLUOROURACIL VIATRIS.

Where to find information in this leaflet:

1. Why am I using FLUOROURACIL VIATRIS?
2. What should I know before I use FLUOROURACIL VIATRIS?
3. What if I am taking other medicines?
4. How do I use FLUOROURACIL VIATRIS?
5. What should I know while using FLUOROURACIL VIATRIS?
6. Are there any side effects?
7. Product details

1. Why am I using FLUOROURACIL VIATRIS?

FLUOROURACIL VIATRIS contains the active ingredient fluorouracil. FLUOROURACIL VIATRIS belongs to a group of anti-cancer medicines that are applied to the skin. It works by destroying precancerous and cancerous cells, while having little effect on normal cells.

FLUOROURACIL VIATRIS is used to treat the following skin conditions:

  • Solar keratoses, also known as actinic keratoses or sunspots.
  • Bowen's disease (type of skin cancer).

Solar keratoses are rough, red, scaly, or crusty spots on the skin that are caused by too much exposure to sunlight. They are more common on sun-exposed areas, such as the face, nose, ears, chest, forearms, and back of the hands.

Solar keratoses are usually harmless, but there is a small risk that they may eventually turn into skin cancer.

Bowen's disease causes one or more small patches of scaly red skin. It occurs when there is a growth of abnormal cells in the outer layer of skin. It is most commonly found on the lower leg.

2. What should I know before I use FLUOROURACIL VIATRIS?

Warnings

Do not use FLUOROURACIL VIATRIS if:

  • you are allergic to fluorouracil, or any of the ingredients listed at the end of this leaflet.
  • Always check the ingredients to make sure you can use this medicine.
  • You have a dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.

Check with your doctor if you:

  • have any other medical conditions including inflammatory skin conditions such as darkening of skin during pregnancy (chloasma) or a chronic rash (rosacea).
  • Work outside for long periods of time during the day.
    Exposure to UV radiation from the sun or tanning salons may increase the intensity of skin reactions at the sites where FLUOROURACIL VIATRIS is applied.
  • Take any medicines for any other condition.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Do not use FLUOROURACIL VIATRIS if you are pregnant or intend to become pregnant. FLUOROURACIL VIATRIS may affect your developing baby if you use it during pregnancy.

Talk to your doctor if you are breastfeeding or intend to breastfeed. Nursing mothers should avoid using FLUOROURACIL VIATRIS as it is not known if the active ingredient in FLUOROURACIL VIATRIS passes into breast milk, and if there is a possibility that your baby may be affected.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with FLUOROURACIL VIATRIS and affect how it works.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect FLUOROURACIL VIATRIS.

4. How do I use FLUOROURACIL VIATRIS?

How much to use

Apply FLUOROURACIL VIATRIS to the affected skin once or twice daily as advised by your doctor.

Follow the instructions below and use FLUOROURACIL VIATRIS until your doctor tells you to stop.

  • Wash the skin to be treated using lukewarm water. Avoid soap or other cleansing products which may sting or irritate your skin, especially as treatment progresses.
  • Pat dry the affected area with a soft white paper towel.
  • Allow 15 minutes for your skin to completely dry.
  • Using a non-metal applicator, cotton bud or a rubber glove apply a thin film of FLUOROURACIL VIATRIS, smoothing it gently onto your affected skin. Do not use too much cream.
  • Be very careful not to allow FLUOROURACIL VIATRIS to come into contact with mucous membranes, such as eyes, eyelids, nostrils and lips.
  • Do not apply FLUOROURACIL VIATRIS to broken skin or open cuts as it is may be absorbed into the bloodstream and may cause side effects.
  • Wash your hands carefully and thoroughly immediately after using FLUOROURACIL VIATRIS.
  • Do not cover the treated area unless your doctor tells you to.
  • If your doctor asks you to apply a dressing after using FLUOROURACIL VIATRIS, apply a fresh dressing to the area(s) daily.
  • The total area of skin treated with FLUOROURACIL VIATRIS at any time should not exceed 500 sq cm (approx. 23 cm x 23 cm). Treat larger areas a section at a time.

When to use FLUOROURACIL VIATRIS

  • Apply in the morning and then again in the late afternoon or early evening.
  • Do not apply FLUOROURACIL VIATRIS immediately before going to bed.
  • Apply FLUOROURACIL VIATRIS at least 1.5 - 2 hours before bedtime to enable complete absorption and prevent wiping off onto pillowcases and sheets. Contact with pillowcases or sheets may result in undesirable spreading of FLUOROURACIL VIATRIS to normal skin that does not need treatment.

How long to use FLUOROURACIL VIATRIS

Unless your doctor tells you to stop using FLUOROURACIL VIATRIS continue treatment up until the ulceration stage, usually 3 to 4 weeks. The healing process is usually complete 1 to 2 months after the end of treatment. The healthy skin surrounding the treated area may occasionally become reddened but will soon resume its normal colour once treatment is stopped.

If you forget to use FLUOROURACIL VIATRIS

FLUOROURACIL VIATRIS should be used regularly at the same time each day.

If you miss your dose at the usual time and it is almost time for your next dose, skip the dose you missed and apply your next dose when you are meant to.

Do not try to make up the dose you missed by applying more the next time.

If you use too much FLUOROURACIL VIATRIS

If you think that you have used too much FLUOROURACIL VIATRIS, you may need urgent medical attention.

You should immediately:

  • phone the Poisons Information Centre
    (Australia telephone 13 11 26) for advice, or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

5. What should I know while using FLUOROURACIL VIATRIS?

What you should expect

Expect your appearance to look worse and to feel uncomfortable while treatment is in progress.

Sometimes it can take several weeks after treatment with FLUOROURACIL VIATRIS has stopped before you see any improvement in your condition.

When FLUOROURACIL VIATRIS is applied to the skin, the following usually happens:

  • Redness of the affected area occurs (generally within 3 to 5 days).
  • This is followed by blistering, peeling, and cracking (within 11 to 14 days) with occasional open sores and some discomfort.
  • The treated skin will then flake away.
  • Some redness of the skin will continue for some time after FLUOROURACIL VIATRIS is stopped. Scarring is not expected.

Things you should do

  • Limit your exposure to sun during and immediately following treatment with FLUOROURACIL VIATRIS.

This will help reduce the likelihood and severity of unwanted side effects.

  • Apply a broad-spectrum sunscreen (SPF 30 or higher) every day before going outdoors, and regularly reapply during the day, except directly on the treatment area.

FLUOROURACIL VIATRIS can make you more sensitive to sunlight. In addition to sunscreen, wear wide-brimmed hat, long sleeves, and trousers (or a long skirt) to protect your skin.

Call your doctor straight away if you:

  • Become pregnant while using FLUOROURACIL VIATRIS.

Remind any doctor, dentist or pharmacist you visit that you are using FLUOROURACIL VIATRIS.

Things you should not do

Do not let FLUOROURACIL VIATRIS come into contact with the eyes, eyelids, nostrils or mouth. FLUOROURACIL VIATRIS is highly irritating to sensitive skin and the eyes.

Things to be careful of

While treatment is in progress follow these personal care tips:

  • Avoid using cosmetics or other topical medications, including sunscreens, directly on the treatment area, unless directed by your doctor.

Your treated skin is expected to become irritated and uncomfortable whilst using FLUOROURACIL VIATRIS.

Applying other products directly on the treatment area may make your discomfort worse.

  • You may continue to shave whilst using FLUOROURACIL VIATRIS but take care not to cut your skin in the treatment area.

As facial skin becomes inflamed during FLUOROURACIL VIATRIS treatment shaving with a conventional razor may become unpleasant. You may prefer instead to lightly shave with an electric razor or clip the facial hair.

Looking after your medicine

Store below 25°C. Protect from heat.

Follow the instructions in the carton on how to take care of your medicine properly.

Store it in a cool dry place away from moisture, heat or sunlight; for example, do not store it:

  • in the bathroom or near a sink, or
  • in the car or on window sills.

Keep it where young children cannot reach it.

Getting rid of any unwanted medicine

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Do not use FLUOROURACIL VIATRIS after the expiry date.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

During treatment with FLUOROURACIL VIATRIS expect to have a temporary unsightly appearance and discomfort at the sites where you apply the cream.

Less serious side effects

Less serious side effectsWhat to do
  • soreness and pain
  • itchiness and irritation
  • darkening or reddening of the skin
  • burning
  • crusting
  • increased sensitivity of the skin to the sun
  • rash
  • dermatitis
  • scarring.
Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effectsWhat to do
  • Stomach problems such as severe pain, cramps, bloody diarrhoea and vomiting
  • Swelling and soreness of the mouth and tongue
  • Fever and chills.
Discontinue FLUOROURACIL VIATRIS immediately and call your doctor straight away or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What FLUOROURACIL VIATRIS contains

Active ingredient
(main ingredient)
fluorouracil 5 %w/w
Other ingredients
(inactive ingredients)
methyl hydroxybenzoate
soft white paraffin
polysorbate 60
propyl hydroxybenzoate
propylene glycol
stearyl alcohol
purified water
Potential allergensmethyl hydroxybenzoate
propyl hydroxybenzoate

Do not take this medicine if you are allergic to any of these ingredients.

What FLUOROURACIL VIATRIS looks like

FLUOROURACIL VIATRIS is a white cream that comes in a 20 g aluminium tube (AUST R 384710).

Who distributes FLUOROURACIL VIATRIS

Sponsor

Accord Healthcare
Level 24, 570 Bourke Street
Melbourne VIC 3000
Australia
Phone: 1800 134 988

Distributor

FLUOROURACIL VIATRIS is distributed in Australia by:
Viatris Pty Ltd
Level 1, 30 The Bond
30-34 Hickson Road
Millers Point NSW 2000
www.viatris.com.au
Phone: 1800 274 276

This leaflet was prepared in February 2022.

FLUOROURACIL VIATRIS_cmi\Apr24/00

Published by MIMS May 2024

BRAND INFORMATION

Brand name

Fluorouracil Viatris

Active ingredient

Fluorouracil

Schedule

S4

 

1 Name of Medicine

Fluorouracil.

2 Qualitative and Quantitative Composition

Contains fluorouracil 5% w/w as the active ingredient.

Excipients with known effect.

Hydroxybenzoates.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Cream.

4 Clinical Particulars

4.1 Therapeutic Indications

Solar and senile keratoses, Bowen's disease.

4.2 Dose and Method of Administration

Fluorouracil Viatris should only be used under medical supervision.
Fluorouracil Viatris is well tolerated. The healthy skin surrounding the area being treated may occasionally become reddened, but soon resumes its normal colour on cessation of treatment.
In cases of senile and solar keratoses a thin layer of the cream is applied to the affected areas once or twice daily, generally without a dressing. In the treatment of other conditions (including keratosis palmaris) a fresh occlusive dressing should be applied daily. Treatment should be continued up to the erosion stage. Duration of therapy is usually 3-4 weeks, but it may prove necessary to exceed this on occasion. When Fluorouracil Viatris is applied to the skin, the following usually happens: a redness of the affected area (generally within 3 to 5 days) followed by blistering, peeling, and cracking (within 11 to 14 days) with occasional open sores and some discomfort. Although the skin seems to be worse, it is a sign that the medication is working. The treated skin will flake away. Some redness of the skin will continue for some time after the drug is stopped.

Limitation of treatment area.

The total area of skin being treated with Fluorouracil Viatris at any time should not exceed 500 sq cm (approx. 23 x 23 cm). Larger areas should be treated a section at a time.

4.3 Contraindications

Fluorouracil is contraindicated in women who are or may become pregnant during therapy (see Section 4.6 Fertility, Pregnancy and Lactation).
Known hypersensitivity to fluorouracil or any of its excipients.
Fluorouracil should not be used in patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency. A large percentage of fluorouracil is catabolised by the enzyme dihydropyrimidine dehydrogenase. DPD enzyme deficiency can result in shunting of fluorouracil to the anabolic pathway, leading to cytotoxic activity and potential toxicities.
Rarely, life-threatening toxicities such as stomatitis, diarrhoea, neutropenia, and neurotoxicity have been reported with intravenous administration of fluorouracil in patients with DPD enzyme deficiency.
A case of life-threatening systemic toxicity has been reported with the topical use of fluorouracil 5% in a patient with DPD enzyme deficiency. Symptoms included severe abdominal pain, bloody diarrhoea, vomiting, fever, and chills. Physical examination revealed stomatitis, erythematous skin rash, neutropenia, thrombocytopenia, inflammation of the oesophagus, stomach, and small bowel. Although this case was observed with 5% fluorouracil cream, it is unknown whether patients with profound DPD enzyme deficiency would develop systemic toxicity with lower concentrations of topically applied fluorouracil.

4.4 Special Warnings and Precautions for Use

The normal pattern of response includes: early and severe inflammatory phases (typically characterised by erythema, which may become intense and blotchy), a necrotic phase (characterised by skin erosion) and finally healing (when epithelialisation occurs). The clinical manifestation of response usually occurs in the second week of fluorouracil treatment. However, these treatment effects sometimes are more severe and include pain, blistering and ulceration.
Fluorouracil is highly irritant, and so should not be allowed to come in contact with mucous membranes (eyes, nose or mouth) due to the possibility of irritation, local inflammation and ulceration. There is a possibility of increased absorption through ulcerated or inflamed skin.
Treatment of perioral area or nasolabial fold should be avoided, or treated carefully. Because of its irritant nature, care should be taken to ensure that fluorouracil does not come into contact with normal skin. Fluorouracil should be applied with a non-metal applicator or rubber glove. Should a glove not be worn and the hands come in contact with fluorouracil during application they should be washed thoroughly after applying fluorouracil.
Exposure to UV-radiation, (e.g. natural sunlight or tanning salon) should be avoided. Fluorouracil therapy is not advisable in persons who work outdoors for prolonged periods in the sun. Excessive sun exposure may produce a diffuse phototoxic response in the areas of application; therefore exposure should be minimised during and immediately following treatment with fluorouracil because the intensity of the reaction may be increased.
While treatment is in progress, avoid cosmetics on treated areas and other topical medication applied to the same area, unless otherwise directed.
Occlusion of the skin with resultant hydration has been shown to increase percutaneous penetration of several topical preparations. If any occlusive dressing is to be used, there may be an increase in the severity of inflammatory reactions in the adjacent normal skin. A porous gauze dressing may be applied for cosmetic reasons without increase in reaction.
The excipients stearyl alcohol and propylene glycol may cause local skin irritations (e.g. contact dermatitis); the excipients methyl hydroxybenzoate and propyl hydroxybenzoate may cause allergic reactions (possibly delayed).

Use in the elderly.

No data available.

Paediatric use.

Safety and effectiveness in children have not been established.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Although no significant medicine interactions with fluorouracil have been reported, potential medicine interactions are possible, caution should be taken with medicines that may have an effect on the DPD enzyme.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data available.
(Category D)
Category D. Drugs which have caused, are suspected to have caused, or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.
Studies in animals have shown that fluorouracil is teratogenic. The potential risk for humans is unknown, hence fluorouracil is contraindicated in pregnancy or where pregnancy cannot be excluded (see Section 4.3 Contraindications).
It is not known whether fluorouracil is excreted in human milk. Because there is some systemic absorption of fluorouracil after topical administration, because many medicines are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants, fluorouracil use should be avoided in nursing mothers.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

The most frequently encountered reactions are often related to an extension of the pharmacological activity of the medicine. These include pain, pruritus, hyperpigmentation, burning, crusting, allergic contact dermatitis, erosions, erythema, hyperpigmentation, irritation, photosensitivity, scarring, rash, soreness and ulceration at the site of application. Leukocytosis is the most frequent haematological adverse effect.
Application site haemorrhage has also been reported (frequency unknown).
The patient should be advised of the temporary unsightly appearance and local discomfort to be expected during treatment with this drug (see Section 4.4 Special Warnings and Precautions for Use). Patients with chloasma and rosacea and other inflammatory dermatoses may encounter accentuation of their condition and should first be treated with appropriate therapy before using the medication. While absorption of fluorouracil through healthy skin is negligible, absorption is considerably increased when it is applied to diseased skin.
Although a causal relationship is remote, other adverse reactions which have been reported infrequently are:

Nervous system disorders.

Dizziness, emotional upset, insomnia, irritability, headache.

Gastrointestinal disorders.

Nausea.

Skin and subcutaneous tissue disorders.

Alopecia, blistering, bullous pemphigoid, discomfort, ichthyosis, scaling, suppuration, swelling, telangiectasia, tenderness, urticarial, skin rash.

Special senses.

Conjunctival reaction, corneal reaction, lacrimation, nasal irritation.

Miscellaneous.

Herpes simplex.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

If fluorouracil is accidentally ingested, signs of fluorouracil overdosage may include nausea, vomiting and diarrhoea. Stomatitis and blood dyscrasias may occur in severe cases. Appropriate measures should be taken for the prevention of systemic infection and daily white cell counts should be performed.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

When the preparation is applied to keratotic and preneoplastic lesions it produces the following pattern of response: first erythema, then, usually, vesiculation, erosion, ulceration, necrosis and epithelialisation.

Clinical trials.

A study was performed to prove the therapeutic equivalence of the test product; Fluorouracil AMEDA (fluorouracil 5% cream) and the reference product; Efudex (fluorouracil 5% cream) which is sold in USA and has been shown to be equivalent to the Australian fluorouracil 5% cream (Efudix). The study type was a randomised, double-blind, placebo-controlled, three-arm parallel assignment, multicentre therapeutic equivalence study with clinical endpoints. The primary objectives were to demonstrate therapeutic equivalence between the afore-mentioned products and to demonstrate superiority over vehicle (placebo) when treating multiple actinic or solar keratosis lesions (AKs) in an adult population. The secondary objective was to compare the adverse event profile of the test and reference products.
A total of 278 adults (mITT population) that had between 5 and 10 clinically typical, visible, discrete, nonhyperkeratotic, non-hypertrophic AK lesions of at least 4 mm on the face and/or bald scalp were assigned to the test, reference or placebo treatment. Subjects were instructed to apply a thin layer of the product to the treatment area on the face and/or bald scalp twice daily (morning and evening) for 2 weeks. 28 days after the treatment ended, final assessment occurred to review the primary efficacy endpoint: the proportion of subjects with 100% clearance of all AK lesions in the treatment area (i.e. complete cure). The results for the test and reference product were 39.1% and 37.2% respectively for the mITT population and 39.2% and 37.8% respectively in the PP population. The difference in proportion between products was 1.5% with an associated adjusted 90% CI of -10.9% to 13.8%, which is well within the equivalence limits of -20% to 20%.
Both the test and reference products were shown to be superior to placebo, and the safety profile of the test product was not clinically different to that of the reference product, with both treatments well tolerated by subjects.

5.2 Pharmacokinetic Properties

No data available.

5.3 Preclinical Safety Data

Genotoxicity.

No data available.

Carcinogenicity.

No data available.

6 Pharmaceutical Particulars

6.1 List of Excipients

Methyl hydroxybenzoate, polysorbate 60, propylene glycol, propyl hydroxybenzoate, purified water, stearyl alcohol and white soft paraffin.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C. Protect from heat.

6.5 Nature and Contents of Container

Tube, aluminium, 20 g.
Pack size: 1 tube per carton.

Australian Register of Therapeutic Goods (ARTG).

AUST R 384710 - Fluorouracil Viatris fluorouracil 5% w/w cream tube.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking it to your local pharmacy.

6.7 Physicochemical Properties

Chemical structure.


CAS number.

51-21-8.

7 Medicine Schedule (Poisons Standard)

S4 (Prescription Only Medicine).

Summary Table of Changes